- Report
- February 2024
- 175 Pages
Global
From €4804EUR$5,000USD£4,131GBP
- Report
- February 2024
- 200 Pages
Global
From €4804EUR$5,000USD£4,131GBP
- Report
- April 2020
Global
From €3843EUR$4,000USD£3,305GBP
- Report
- January 2022
- 60 Pages
Global
From €1441EUR$1,500USD£1,239GBP
- Report
- August 2019
- 30 Pages
China
From €2114EUR$2,200USD£1,818GBP
- Report
- January 2019
- 30 Pages
China
From €2114EUR$2,200USD£1,818GBP
- Report
- December 2022
- 217 Pages
Global
From €3459EUR$3,600USD£2,974GBP
- Report
- December 2022
- 79 Pages
North America
From €1441EUR$1,500USD£1,239GBP
- Report
- December 2022
- 90 Pages
Europe
From €1441EUR$1,500USD£1,239GBP
- Report
- May 2021
- 71 Pages
Global
From €3200EUR$3,568USD£2,848GBP
- Report
- May 2024
- 50 Pages
Global
From €2546EUR$2,650USD£2,189GBP
- Report
- May 2024
- 50 Pages
Global
From €2546EUR$2,650USD£2,189GBP
- Report
- May 2023
- 147 Pages
Global
From €5764EUR$5,999USD£4,956GBP
Clomifene, also known as clomiphene, is a drug used in the treatment of infertility in women. It works by stimulating the release of hormones that help to produce eggs in the ovaries. Clomifene is used to treat anovulation, a condition in which the ovaries do not produce eggs regularly. It is also used to treat polycystic ovary syndrome, a condition in which the ovaries produce too many hormones. Clomifene is also used to induce ovulation in women who are not ovulating regularly.
Clomifene is a popular drug in the sexual and reproductive health market, as it is used to treat a variety of conditions related to fertility. It is a safe and effective treatment for many women, and is often prescribed as a first-line treatment for infertility.
Some companies in the Clomifene market include Teva Pharmaceuticals, Mylan, and Sandoz. Show Less Read more